MRNA, XERS and VIR hit 52-week highs on earnings and trial optimism
Moderna, Xeris and Vir shares reached 52-week highs on Friday after analyst target increases, strong Q3 results and positive Phase 3 data for Vir, per Stocktwits.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Stocktwits, shares of Moderna (MRNA), Xeris Biopharma (XERS) and Vir Biotechnology (VIR) reached 52-week highs on Friday. Moderna closed more than 5% higher after several analysts lifted their price targets following strong third-quarter results, with revenue of $1.31 billion and GAAP net income of $0.16 billion. Xeris jumped more than 16% after raising its 2030 revenue outlook to over $1 billion from about $750 million. Vir rose nearly 11% ahead of expanded data from its Phase 2 Solstice trial, after announcing positive topline results from the Phase 3 Eclipse 1 study over the weekend.
why it matters
Analyst target changes often reflect market sentiment more than changes in fundamentals. These rallies rest on expectations for new trial data and revenue momentum, so market participants will watch whether the move holds.
market impact
Biotech stocks MRNA, XERS, VIR: gains on earnings and trial optimism
- MRNA pressure up — analysts raising price targets after strong third-quarter results
- XERS pressure up — higher revenue outlook and growing investor interest after quarterly results
- VIR pressure up — anticipation of expanded trial data and positive Phase 3 topline results
tags
instruments
sources
- Why Did MRNA, XERS, VIR Stocks Surge To 52-Week Highs Last Week? — Stocktwits, 9 November 2026 at 04:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗